Table 1.
Exposure pattern and corresponding effect
| Exposure (Co-60) | Screening (stage I) mRNA and miRNA | Validation (stage II, all available samples) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| mRNA | miRNA | ||||||||||||
| ID no. | Radiation dose (Gy, free in air) | PBI/TBI | Days after exposure | HARS degree | H0 | HARS with pancytopenia | HARS without pancytopenia | H0 | HARS with pancytopenia | HARS without pancytopenia | H0 | HARS with pancytopenia | HARS without pancytopenia |
| 1 | 5 PBI 50% | Left-hemibody exposed | 0 | 0 | 0 day | 0 day | |||||||
| 1 | 2 | 1 day | 1 day | ||||||||||
| 2 | 2 | 2 days | 2 days | ||||||||||
| 2 | 5 PBI 50% | Left-hemibody exposed | 0 | 0 | 0 day | 0 day | 0 day | ||||||
| 1 | 2 | 1 day | 1 day | ||||||||||
| 2 | 2 | 2 days | 2 days | ||||||||||
| 3 | 15 PBI 30% | Head + arms exposed | 0 | 0 | 0 day | 0 day | 0 day | ||||||
| 1 | 1–2 | 1 day | 1 day | ||||||||||
| 2 | 1–2 | 2 days | 2 days | ||||||||||
| 4 | 15 PBI 30% | Head + arms exposed | 0 | 0 | 0 day | 0 day | 0 day | ||||||
| 1 | 1–2 | 1 day | 1 day | ||||||||||
| 2 | 1–2 | 2 days | |||||||||||
| 5 | 6.25 PBI 80% | 2 legs shielded | 0 | 0 | 0 day | 0 day | |||||||
| 1 | 2–3 | 1 day | 1 day | ||||||||||
| 2 | 2–3 | 2 days | |||||||||||
| 6 | 6.25 PBI 80% | 2 legs shielded | 0 | 0 | 0 day | 0 day | |||||||
| 1 | 2 | 1 day | 1 day | ||||||||||
| 2 | 2 | 2 days | 2 days | ||||||||||
| 7 | 10 PBI 50% | Left-hemibody exposed | 0 | 0 | 0 day | 0 day | |||||||
| 1 | 1–2 | 1 day | 1 day | ||||||||||
| 2 | 1–2 | 2 days | 2 days | ||||||||||
| 8 | 10 PBI 50% | Left-hemibody exposed | 0 | 0 | 0 day | 0 day | |||||||
| 1 | 1–2 | 1 day | 1 day | ||||||||||
| 2 | 1–2 | 2 days | 2 days | ||||||||||
| 9 | 5.55 PBI 90% | 1 leg shielded | 0 | 0 | 0 day | 0 day | |||||||
| 1 | 3 | 1 day | |||||||||||
| 2 | 3 | 2 days | |||||||||||
| 10 | 5 TBI | TBI | 0 | 0 | 0 day | 0 day | 0 day | ||||||
| 1 | 2 | 1 day | 1 day | ||||||||||
| 2 | 2 | 2 days | 2 days | ||||||||||
| 11 | 7.5/2.5 TBI | TBI | 0 | 0 | 0 day | 0 day | |||||||
| 1 | 3 | 1 day | 1 day | ||||||||||
| 2 | 3 | 2 days | 2 days | 2 days | |||||||||
| 12 | 5.55 PBI 90% | 1 leg shielded | 0 | 0 | 0 day | 0 day | |||||||
| 1 | 2 | 1 day | 1 day | 1 day | |||||||||
| 2 | 2 | 2 days | 2 days | 2 days | |||||||||
| 13 | 6.25 PBI 80% | 2 legs shielded | 0 | 0 | 0 day | 0 day | |||||||
| 1 | 2 | 1 day | 1 day | ||||||||||
| 2 | 2 | 2 days | 2 days | ||||||||||
| 14 | 6.25 PBI 80% | Head neck shielded | 0 | 0 | 0 day | 0 day | |||||||
| 1 | 2 | 1 day | 1 day | 1 day | |||||||||
| 2 | 2 | 2 days | 2 days | 2 days | |||||||||
| 15 | 2.5 TBI | TBI | 0 | 0 | 0 day | 0 day | |||||||
| 1 | 2–3 | 1 day | 1 day | 1 day | |||||||||
| 2 | 2–3 | 2 days | 2 days | ||||||||||
| 16 | 2.5 TBI | TBI | 0 | 0 | 0 day | 0 day | |||||||
| 1 | 2–3 | 1 day | 1 day | ||||||||||
| 2 | 2–3 | 2 days | 2 days | ||||||||||
| 17 | 5 TBI | TBI | 0 | 0 | 0 day | 0 day | |||||||
| 1 | 2 | 1 day | 1 day | 1 day | |||||||||
| 2 | 2 | 2 days | 2 days | 2 days | |||||||||
| 0 day #5 | 1 day #5; 2 days #5 | 1 day #5; 2 days #5 | 0 day #17 | 1 day #3; 2 days #2 | 1 day #7; 2 days #6 | 0 day #16 | 1 day #5; 2 days #5 | 1 day #12; 2 days #12 | |||||
The left part of the table summarizes radiation exposure scenarios and resulting hematologic acute radiation syndrome (HARS) severities and a time scale with days after irradiation. Partial body irradiation (PBI) and total body irradiation (TBI) were performed, and details on PBI are summarized below the subtitle. The TBI 7.5/2.5 Gy represents a sequential protocol of irradiation using 2.5 Gy TBI at first followed by an additional 5 Gy exposure with hemibody shielding. Exposure between the two fractions was stopped for 5 min. The right part of the table shows blood samples used for screening at stage I followed by the blood samples used for a validation of mRNA and miRNA species (using all available blood samples including those remaining from stage I). The total number of blood samples used for stage I and stage II are summed up on the bottom of each column